Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 37.65
Bid: 37.20
Ask: 37.50
Change: -0.125 (-0.33%)
Spread: 0.30 (0.806%)
Open: 37.30
High: 37.65
Low: 37.00
Prev. Close: 37.475
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licenses CSD500 to Church & Dwight

2 Apr 2013 07:00

RNS Number : 2832B
Futura Medical PLC
02 April 2013
 



For immediate release

2 April 2013

 

 

Futura Medical PLC

("Futura" or the "Company")

 

Futura licenses CSD500 to Church & Dwight

 

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that it has signed a licensing deal with Church & Dwight Co Inc, the major US consumer products group whose brands include Trojan® condoms, for the marketing and distribution of CSD500, Futura's novel condom.

 

Trojan® is the number one condom brand in North America and the world's second biggest condom brand by product sales.

 

Under the terms of the agreement, Church & Dwight will hold the rights to manufacture, market and distribute CSD500 in North America and in a number of key European territories.

 

The financial details of the agreement are not being disclosed although Futura will receive an upfront payment and royalties on all product sales along with certain minimum performance guarantees.

 

Adrian Huns, Church & Dwight's President of International Consumer Products, commented: "CSD500 is a genuinely novel condom that marks a major breakthrough in condom technology. We look forward to working with Futura on the successful completion of the required approvals necessary ahead of the launch in Europe and North America of a completely new type of condom from a highly trusted brand."

 

James Barder, Futura's Chief Executive, commented: "We are delighted to sign this pivotal agreement with Church & Dwight for the marketing of CSD500 as a Trojan®-branded condom in North America and in key territories in Europe. Trojan® is one of the world's biggest condom brands and the number one brand in North America."

 

"The agreement is in line with the Board's preferred strategy of licensing CSD500 on a geographic basis to condom distributors that hold leading positions in their regions. We continue to negotiate CSD500 rights for other major territories and believe that this strategy will create optimal value for shareholders."

 

 

For further information:

 

Futura Medical plc

+ 44 (0) 1483 685 670

James Barder, Chief Executive

Mail to: James.Barder@futuramedical.com

www.futuramedical.com

Nomura Code Securities Limited

+ 44 (0) 20 7776 1200

Phil Walker / Giles Balleny

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes to editors:

 

About Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCNKBDQPBKKNQK
Date   Source Headline
13th Sep 201911:46 amRNSHolding(s) in Company
12th Sep 20199:05 amRNSSecond Price Monitoring Extn
12th Sep 20199:00 amRNSPrice Monitoring Extension
11th Sep 20194:40 pmRNSSecond Price Monitoring Extn
11th Sep 20194:35 pmRNSPrice Monitoring Extension
11th Sep 20197:00 amRNSInterim Results for Six Months ended 30 June 2019
10th Sep 20197:00 amRNSFutura Announces Joint Venture Collaboration
16th Aug 20194:37 pmRNSHolding(s) in Company
12th Aug 20193:21 pmRNSDirector/PDMR Shareholding
12th Aug 20197:00 amRNSNotice of Interim Results
23rd Jul 20192:06 pmRNSSecond Price Monitoring Extn
23rd Jul 20192:00 pmRNSPrice Monitoring Extension
5th Jul 20193:54 pmRNSHolding(s) in Company
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:36 pmRNSPrice Monitoring Extension
25th Jun 20194:47 pmRNSDirector/PDMR Shareholding
24th Jun 20194:42 pmRNSAGM Statement
24th Jun 20197:00 amRNSAGM Statement
19th Jun 20197:00 amRNSRecruitment completed for MED2005 Phase 3 study
30th May 20197:00 amRNSNotice of AGM
30th May 20197:00 amRNSBlock listing Interim Review
29th May 201910:47 amRNSHolding(s) in Company
23rd May 20197:00 amRNSLiberum Appointed as Nominated Adviser & Broker
8th May 20192:05 pmRNSSecond Price Monitoring Extn
8th May 20192:00 pmRNSPrice Monitoring Extension
7th May 20199:05 amRNSSecond Price Monitoring Extn
7th May 20199:00 amRNSPrice Monitoring Extension
3rd May 20192:05 pmRNSSecond Price Monitoring Extn
3rd May 20192:00 pmRNSPrice Monitoring Extension
16th Apr 20196:05 pmRNSHolding(s) in Company
10th Apr 20197:00 amRNSPreliminary Results for the year ended 31 Dec 2018
5th Mar 20197:00 amRNSNotice of Preliminary Results
20th Feb 20191:10 pmRNSHolding(s) in Company
14th Feb 20197:00 amRNSFutura to host EU Advisory Panel Meeting at ESSM
13th Feb 20195:04 pmRNSHolding(s) in Company
13th Feb 20194:40 pmRNSSecond Price Monitoring Extn
13th Feb 20194:35 pmRNSPrice Monitoring Extension
8th Feb 20199:55 amRNSHolding(s) in Company
6th Feb 20197:00 amRNSHolding(s) in Company
1st Feb 20197:00 amRNSTotal Voting Rights
28th Jan 20197:00 amRNSPresentation at the 21st ESSM Congress
23rd Jan 20195:38 pmRNSHolding(s) in Company
22nd Jan 201911:05 amRNSSecond Price Monitoring Extn
22nd Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20193:56 pmRNSHolding(s) in Company
11th Jan 201911:01 amRNSRemuneration of Non-Executive Directors and TVR
8th Jan 201911:00 amRNSPrice Monitoring Extension
3rd Jan 20194:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20194:35 pmRNSPrice Monitoring Extension
17th Dec 20187:00 amRNSFutura Medical to Host R&D Day in February 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.